18 results about "Chromatosome" patented technology

This invention relates to the fields of biomedical engineering and embryo quality assessment, and particularly to a biomarker for assessing the quality of IVM-derived embryos and its application. The biomarker includes time point parameters t2 and t9 of the IVM-derived embryos, and time interval parameters S2, t9–t7, t9–t8, or tSB–t9. A method for assessing the quality of IVM-derived embryos based on the aforementioned biomarker has been established. This method combines non-invasive temporal imaging technology with morphodynamic multi-parameter analysis, providing a reliable tool for assessing the blastocyst formation potential and chromosomal euploidy of IVM-derived embryos in clinical practice, thus potentially expanding the application of IVM technology in assisted reproductive technology.

The present invention relates to a method for detecting chromosomal structural variations using chromosome conformation capture technology and high-throughput sequencing technology, as well as detection products for use in the method, and diagnostic applications of the method and products, in particular in prenatal screening.

The invention relates to a group of Y-chromosomal short tandem repeat (Y-STR) markers comprising at least one rapidly mutating (RM) Y-STR marker selected from the group consisting of DYF1000, DYF1001, DYF1002, DYR88, DYS685, DYS688, DYS712, DYS1003, DYS1007, DYS1010 and DYS1012. The invention further relates to a set of amplification primers comprising primers for the amplification of at least one Y-STR marker according to the invention, to methods for amplifying an allele of at least one Y-STR marker, to a kit for identifying an allele of a Y-STR marker by amplification and electrophoretic detection or sequencing detection, and by sequencing of non-amplified DNA, and to the use of the group of Y-STR markers for typing male individuals.

Disclosed herein are systems and methods for performing secondary analysis of nucleotide sequencing data in a time-efficient manner. Some embodiments include iteratively performing secondary analysis as sequence reads are generated by a sequencing system. Secondary analysis can include alignment of sequence reads to a reference sequence (e.g., a human reference genome sequence) and use of the alignment to detect differences between a sample and the reference. Secondary analysis can be capable of detecting genetic differences, variant calling and genotyping, identifying single nucleotide polymorphisms (SNPs), small insertions and deletions (indels), and structural changes in DNA, such as copy number variations (CNVs) and chromosomal rearrangements.

The application discloses a SNP molecular marker related to intramuscular fat content of Laiwu pigs and application thereof, and belongs to the technical field of molecular biology. The SNP molecular marker corresponds to a SNP site located at 27,674,494 bp of chromosome 10 in the 11.1 version of an international pig reference genome, and is located in a chromatin open region of a CTSL gene; the chromatin open region comprises a positive strand sequence as shown in SEQ ID NO. 1 and an antisense strand sequence as shown in SEQ ID NO. 2; a T / C polymorphism exists at the 206th base of the SEQ ID NO. 1, and an A / G polymorphism exists at the 377th base of the SEQ ID NO. 2. By detecting the SNP molecular marker, early judgment of intramuscular fat content can be realized at a piglet stage of the Laiwu pigs, a breeding cycle is greatly shortened, breeding cost is reduced, and the stability of the high intramuscular fat content trait of the Laiwu pigs is effectively maintained, so that the application has important application value for Laiwu pig breeding.

The invention relates to a hybridization probe mixed solution for radiation biological dose detection as well as a preparation method and a product thereof, and belongs to the field of molecular cell genetics. The technical problem to be solved is to provide a hybridization probe mixed solution with significantly improved chromosome distortion recognition accuracy and sensitivity, higher detection efficiency and better repeatability. According to the key point of the technical scheme, the hybridization probe mixed solution is composed of a probe and a hybridization buffer solution, the volume ratio of the probe to the hybridization buffer solution is 1: (50-1000); the hybridization buffer solution is a 40%-70% formamide solution containing 10 to 20 mM of Tris-HCl or PBS (Phosphate Buffer Solution). When the hybridization probe mixed solution is used for radiation biological dose detection, the distortion identification accuracy and sensitivity are high, the radiation dose estimation precision is high, and the operation is convenient.

This invention discloses a set of KASP primers related to wheat grain weight and their applications. The primer set includes primers with nucleotide sequences as shown in SEQ ID NO.7, SEQ ID NO.8, and SEQ ID NO.6. This KASP primer set can be used to detect loci on wheat chromosome 5D that are associated with thousand-grain weight. Ktkw-5D, Allele C / T typing was performed at this locus. Wheat carrying allele C had a significantly higher thousand-grain weight than wheat carrying allele T, thus enabling early screening of wheat grain weight and accelerating the breeding process.

The present application relates to the assisted evaluation method of the second biopsy in the pre-implantation genetic testing. The blastocyst first biopsy process collects and cryopreserves the corresponding biopsy droplet; for the blastocyst with CNV detection failure or suspected abnormal CNV detection result in the first biopsy cell, the first biopsy droplet is thawed to complete genome amplification, CNV library construction, high-throughput sequencing and CNV analysis, and the second biopsy suggestion is given according to the detection result. If the biopsy droplet detects the abnormal aneuploidy or chimera clinically interpreted, it is suggested that the corresponding blastocyst has a high probability of chromosomal abnormality, and the second biopsy is not recommended; if the biopsy droplet does not detect the abnormal aneuploidy or chimera clinically interpreted, it is suggested that the corresponding blastocyst has a high probability of chromosomal normality, and the second biopsy is recommended. The present application proves that the first biopsy droplet contains detectable genetic material, and the consistency of the chromosomal ploidy detection result and the biopsy cell is more than 80%, which can assist the second biopsy decision and improve the decision efficiency and scientificity of PGT detection.

A Shigella vaccine preparation comprising 10E8-10E12 CFU of a live, genetically attenuated Shigella flexneri strain that comprises a chromosomal deletion of setBA and which is non-invasive as determined by the Sereny test and an in vitro invasion assay using HeLa cells, wherein the strain comprises an endogenous invasion plasmid that is genetically engineered to incorporate a heterologous expression construct expressing a pathogen-specific antigen.

Disclosed herein are agents, compositions and methods for increasing the developmental potential of human preimplantation embryos. Disclosed herein are methods of reducing or decreasing replication abnormalities and / or aneuploidies in an embryo as well as increasing genome stability and / or developmental potential of an embryo by activating kinases and / or their signaling pathway in an oocyte including but not limited to ATR, WEE1, and CHK1. Also disclosed herein are methods of reducing or decreasing replication abnormalities and / or aneuploidies in an embryo as well as increasing genome stability and / or developmental potential of an embryo using polynucleotides, polypeptides and / or agents which increase efficiency of the "fork reversion and repair" pathway and / or decrease detrimental outcomes such as fork collapse, tranlesion synthesis and / or gap formation. Lastly disclosed herein are methods of reducing or decreasing replication abnormalities and / or aneuploidies in an embryo as well as increasing genome stability and / or developmental potential of an embryo using one or more polynucleotides or polypeptides including but not limited to CHEK1, WEE1, ETAA1, ATRX, BLM, BRCA2, CHD4, DNA2 (DNA2L), EXO1, FANCC, FANCG, FBH1 (FBXO18), HLTF (SMARCA3), MCM9, MSH6, POLD3, POLK, RAD51, RAD52, RAD54L, RBI, RECQL, REV3L, RIF1, RNF8, SETD1A, SHPRH, SMARCAL1, TDRD3, TOPBP1, TP53BP1, WRNIP1, XRCC2, WRN, BRCA1, ZRANB3, CDC6, CDT1, POLH, POLI, FANCD2, INO80, FANCB, ASH2L, FAM35A, XRCC3, BRIP1, and RNF168.

Methods and systems to assess the viability of human oocytes for egg vitrification or cryopreservation process are disclosed herein. The method utilizes fluorescence lifetime imaging microscopy (FLIM) coupled with integrating an oocyte's morphological endpoints, such as shape and size, to assess and identify the viability in human oocytes. The method and system also use data analysis software capable of correlating PH values, FLIM data, and chromosomal health assessments to determine the viability of human oocytes.

The present invention relates to a composition for use in hybridization, the composition comprising: (a) at least one hybridization probe (“component (a)”); (b) at least one polar protic or polar aprotic solvent (“component (b)”) having a cyclic molecule structure; and (c) at least one carboxylic acid amide and / or salts thereof (“component (c)”), in an amount of more than 10 vol %, based on the composition. The invention furthermore relates to a use of this composition, and to methods for detecting nucleic acids and / or chromosomal aberrations in a biological sample by way of hybridization, using the composition.

The application discloses a methylation marker combination of esophageal cancer and application, a kit, a system, a model construction method and a nucleic acid fragment combination. The methylation marker combination of the esophageal cancer comprises at least 10 regions in 37 chromosomal regions defined by Hg38 coordinates. The methylation marker combination of the esophageal cancer provided by the application has high sensitivity to the esophageal cancer, and can be used for early screening of esophageal cancer risk and screening of the esophageal cancer.

This invention discloses a method and detection kit for assessing molecular risk status associated with hepatocellular carcinoma (HCC). The method involves obtaining biological samples, isolating exosomes and their extrachromosomal circular DNA (eccDNA), and using a conformation-selective detection element to detect the conformational state of at least one target gene region associated with HCC. Conformation binding signals are obtained, and the conformation binding index (CBI) is calculated. Molecular risk stratification results are generated based on the index. The kit includes sample processing components, a conformation detection element, and a result indication system. It is used to assess molecular risk status associated with HCC and is not intended for disease diagnosis, staging, or treatment decisions. It is suitable for molecular risk assessment or risk stratification of non-invasive samples.

The present disclosure provides a method of identifying lung cancer in a subject in need there of comprising detecting circulating genetically abnormal cells (CGAC) in a sample comprising a population of cells. CGACs can be identified and classified according chromosomal hybridization patterns detected via fluorescent in situ hybridization (FISH). The identification of lung cancer can also comprise the evaluation of at least one nuclear parameter in the CGAC and / or identifying the presence or absence of an intracellular or cell surface protein in the CGAC.

The present invention relates to a method, in particular an in vitro method, for identifying memory B cells, comprising analyzing epigenetic modifications / properties of (including the methylation status) of at least one CpG position in the mammalian gene region for Chromobox protein homolog 6 (CBX6), wherein a demethylation or lack of methylation of said gene region is indicative for a memory B cell, when compared to a non-memory B cell. The analyses according to the invention can identify memory B cells on an epigenetic level and distinguish them from all other cells in complex samples, such as, for example, other blood or immune cells. The resent invention furthermore provides an improved method for quantifying memory B cells, in particular in complex samples. The method can be performed without a step of purifying and / or enriching cells, preferably in whole blood and / or non-trypsinized tissue.

Described are methods of characterizing chromosomal instability in a DNA sample obtained from a tumor, the method comprising: obtaining a tumor copy number profile of the sample; for each of one or more segments in the copy number profile, quantifying a set of copy number features, wherein the set of copy number features consists of copy number features associated with the respective segment; and for a segment of the one or more segments, using features quantified for the segment, determining a measure indicative of an association between one or more chromosomal instability signature features and the segment, wherein a signature feature of chromosomal instability comprises a set of weights for each of a plurality of components, each component being associated with a copy number feature in the set of copy number features, wherein the weights indicate a probability that a mutational process associated with the signature feature produces segments having characteristics defined by the components.